Tissue-restricted genome editing in vivo specified by microRNA-repressible anti-CRISPR proteins

CRISPR-Cas systems are bacterial adaptive immune pathways that have revolutionized biotechnology and biomedical applications. Despite the potential for human therapeutic development, there are many hurdles that must be overcome before its use in clinical settings. Some clinical safety concerns arise...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Jooyoung, Mou, Haiwei, Ibraheim, Raed, Liang, Shun-Qing, Liu, Pengpeng, Xue, Wen, Sontheimer, Erik J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cold Spring Harbor Laboratory Press 2019
Materias:
Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6795140/
https://www.ncbi.nlm.nih.gov/pubmed/31439808
http://dx.doi.org/10.1261/rna.071704.119

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6795140/
https://www.ncbi.nlm.nih.gov/pubmed/31439808
http://dx.doi.org/10.1261/rna.071704.119

Ejemplares similares